Technical Analysis for ASND - Ascendis Pharma A/S

Grade Last Price % Change Price Change
B 94.95 0.94% 0.88
ASND closed up 0.94 percent on Thursday, September 28, 2023, on 71 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Down

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Hammer Candlestick Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Lower Bollinger Band Touch Weakness 0.00%
50 DMA Resistance Bearish 0.94%
MACD Bearish Centerline Cross Bearish 0.94%
Fell Below 50 DMA Bearish 0.79%
Inside Day Range Contraction 0.79%
50 DMA Support Bullish -0.58%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Support about 9 hours ago
Rose Above 50 DMA about 9 hours ago
Lower Bollinger Band Support about 11 hours ago
60 Minute Opening Range Breakdown about 12 hours ago
Fell Below Lower Bollinger Band about 12 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ascendis Pharma A/S Description

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Diabetes Hypertension Insulin Hormones Pulmonary Arterial Hypertension Breakthrough Therapy Peptide Hormones Drug Therapies Growth Hormone Treatment Of Diabetes Growth Hormone Deficiency Recombinant Proteins Growth Hormone Therapy Prodrug Treprostinil

Is ASND a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 134.48
52 Week Low 64.33
Average Volume 283,175
200-Day Moving Average 99.81
50-Day Moving Average 94.91
20-Day Moving Average 98.73
10-Day Moving Average 96.76
Average True Range 3.63
RSI (14) 45.65
ADX 18.85
+DI 14.99
-DI 27.12
Chandelier Exit (Long, 3 ATRs) 95.57
Chandelier Exit (Short, 3 ATRs) 102.47
Upper Bollinger Bands 105.33
Lower Bollinger Band 92.13
Percent B (%b) 0.21
BandWidth 13.37
MACD Line -0.25
MACD Signal Line 0.73
MACD Histogram -0.9858
Fundamentals Value
Market Cap 5.07 Billion
Num Shares 53.4 Million
EPS -5.09
Price-to-Earnings (P/E) Ratio -18.64
Price-to-Sales 753.04
Price-to-Book 7.67
PEG Ratio -0.27
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 100.13
Resistance 3 (R3) 99.59 97.31 99.27
Resistance 2 (R2) 97.31 95.99 97.59 98.98
Resistance 1 (R1) 96.13 95.18 96.72 96.68 98.69
Pivot Point 93.86 93.86 94.15 94.13 93.86
Support 1 (S1) 92.68 92.54 93.27 93.22 91.21
Support 2 (S2) 90.40 91.72 90.68 90.92
Support 3 (S3) 89.22 90.40 90.63
Support 4 (S4) 89.77